



## **Viamet to Present at the 3<sup>rd</sup> Annual Dermatology Summit**

### ***One of Eight Companies Selected to Present at Entrepreneurial Showcase***

RESEARCH TRIANGLE PARK, N.C., Jan. 7, 2016, – [Viamet Pharmaceuticals, Inc.](http://www.viamet.com) today announced that the company will present at the 3<sup>rd</sup> Annual Dermatology Summit. The conference will take place on January 10, 2016 from 9:30 am to 7:00 pm PST at the Palace Hotel in San Francisco, CA.

The Viamet presentation will highlight VT-1161, a novel, highly potent and selective, oral inhibitor of fungal CYP51, a well-validated antifungal target. During the presentation, Amir Tavakkol, Ph.D., Viamet Chief Development Officer, will provide an update on the company's ongoing RENOVATE Phase 2b clinical trial of VT-1161 for the oral treatment of toenail onychomycosis.

"We are honored to be among only eight companies selected to present during the Entrepreneurial Company Showcase at this prestigious conference," commented Dr. Tavakkol. "VT-1161 has the opportunity to be a significant new therapeutic option for the treatment of onychomycosis and we are pleased that the conference organizers have recognized its potential by selecting us to present."

#### **About VT-1161**

VT-1161 is a potent and selective, orally-administered inhibitor of fungal CYP51 currently in Phase 2b clinical trials for the treatment of onychomycosis and recurrent vulvovaginal candidiasis (RVVC). VT-1161 blocks the production of ergosterol, an essential component of the fungal cell membrane. In preclinical and clinical studies, VT-1161 has demonstrated broad-spectrum activity against both dermatophytes and Candida species, including those species that cause onychomycosis and RVVC. Because VT-1161 is highly selective for fungal CYP51, the Company believes that it may avoid the side effects that limit the use of current oral antifungal therapies, such as liver toxicity and drug-drug interactions.

#### **About Onychomycosis**

Onychomycosis is a fungal infection that involves the nail matrix, nail bed, and nail plate. Onychomycosis can cause discoloration, thickening and splitting of the nail, as well as separation of the nail plate from the nail bed. The condition may result in pain when walking, thereby limiting ambulation. Onychomycosis can also be a significant medical issue for diabetics or other patients with compromised immune systems. In these patients, the infected nail can serve as an entry point for bacterial infection, which can in turn lead to serious complications such as amputation. An estimated 32 million individuals in the United States suffer from onychomycosis.

#### **About the RENOVATE Study**

RENOVATE (**RE**storing **N**ail; an **O**ral **VT-1161** **T**ablet **E**valuation), is an ongoing randomized, double-blind, placebo-controlled Phase 2b clinical trial in patients with toenail onychomycosis at clinical sites across the United States. The study will evaluate two dose levels of VT-1161 administered once weekly for either 10 or 22 weeks following an initial two-week once-daily loading dose period. The primary endpoint will be the percentage of patients achieving complete cure of the target nail at week 48 of the study. Viamet previously reported robust antifungal activity and a very favorable safety profile in a Phase 2a proof-of-concept study in the treatment of tinea pedis, or athlete's foot.

#### **About Viamet ([www.viamet.com](http://www.viamet.com))**

Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs.



**Media Contact:**

Blair McCarthy Atkinson  
MacDougal Biomedical Communications  
Direct: +1 812 454 6257  
Main: +1 781 235 3060  
[batkinson@macbiocom.com](mailto:batkinson@macbiocom.com)

**Investor Contact:**

John Woolford  
Westwicke Partners  
Direct: +1 443 213 0506  
[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)

*This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies are based in the Research Triangle Park region of North Carolina, USA.*